CN102153521B - Intermediate for preparing linezolid and preparation method thereof - Google Patents
Intermediate for preparing linezolid and preparation method thereof Download PDFInfo
- Publication number
- CN102153521B CN102153521B CN201110033294A CN201110033294A CN102153521B CN 102153521 B CN102153521 B CN 102153521B CN 201110033294 A CN201110033294 A CN 201110033294A CN 201110033294 A CN201110033294 A CN 201110033294A CN 102153521 B CN102153521 B CN 102153521B
- Authority
- CN
- China
- Prior art keywords
- structural formula
- compound
- preparation
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C[C@@](CN1c(cc2F)ccc2N2CCOCC2)OC1=O Chemical compound *C[C@@](CN1c(cc2F)ccc2N2CCOCC2)OC1=O 0.000 description 1
- OLDRPBWULXUVTL-LLVKDONJSA-N OC[C@@H](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O Chemical compound OC[C@@H](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O OLDRPBWULXUVTL-LLVKDONJSA-N 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The invention relates to an intermediate compound of a chemical synthetic drug and a preparation method thereof, in particular to an intermediate compound for preparing linezolid and a preparation method thereof. The preparation method has the advantages of cheap and readily-available raw materials, short process route, low cost, mild and safe reaction process condition and no use of device with special requirements, and is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of field of midbody compound and preparation method thereof of chemical synthetic drug, particularly, the present invention relates to midbody compound for preparing Linezolid (Linezolid) and preparation method thereof.
Background technology
Bacterial resistance is one of serious problems of facing of the whole world clinical and public health, and Linezolid is because its unique chemical structure and mechanism of action to drug tolerant bacteria, particularly have good killing effect to resistance of vancomycin property of medicine bacterium.Linezolid (Linezolid; Structural formula IV); Chemical name (S)-N-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxygen-5-oxazolidinyl] methyl] ethanamide; Be first oxazolidine ketone antimicrobial drug that Pfizer released in 2000, be mainly used in treatment drug resistant bacterial infections and surgical infection.
Synthesizing of relevant Linezolid, the technology of bibliographical information can be divided into two types substantially: one type is sodium azide technology, and one type is non-sodium azide technology.Early stage technology is sodium azide technology mostly, and is as shown in Figure 1.Different is the technology difference of preparation structural formula V or structural formula VI compound.Like US5688792, US6107519, US7291614, WO2009063505, CN200910101973.3, J.Med Chem 1996; 339:673; Chinese Journal of New Drugs 2002; 11:378; China's pharmaceutical chemistry magazine 2005; 15:89 etc.
Sodium azide technology is owing to the sodium azide explosive, and safety in production has a big risk and is not suitable for amplifying and producing.Therefore non-sodium azide technology is the emphasis of research always.Non-sodium azide technology the earliest is the inferior acid amides technology of phthalic acid such as Fig. 2.This technology is with structural formula IX compound; Use the hydrazine hydrolysis; Obtain structural formula VIII compound, and then acetylize gets Linezolid [US5688792, WO9924393 (CN98810019.3), WO2005099353, US7429661, US2006008754, Chinese pharmaceutical chemistry magazine 2003; 13:28]
The shortcoming of this technology is during by structural formula IX compound structural formula V III compound, and hydrazinolysis needs more violent condition, is prone to cause the oxazole ring and decomposes, and causes the product Linezolid to be difficult for purifying, and yield is low.
The technology that world patent WO9737980 (CN97193658.7) (G is a hydrogen), WO2010031769 (G is allyl group, substituted allyl or quaternary carbon alkyl) and WO2010084514 (G is benzyl or substituted benzyl) disclose is the non-repeatedly nitrogen technology of another kind of synthetic Linezolid; Its reduction is for amine foundry skill, as shown in Figure 3.
This technology be with structural formula VI compound carry out that ammonia is separated or with primary amine generation substitution reaction, take off alkyl again and obtain structural formula VIII compound.The shortcoming of this technology be ammonia separate or amine for the time, in secondary amine generation, take place easily, even three amine generations, be difficult to remove, influence quality.
World patent WO9924393 (CN98810019.3), WO2002085849, Org.Proce.Res Dev2003; 7:533, West China pharmaceutical journal 2007; 22:179 etc. have also reported a kind of non-repeatedly nitrogen technology, and this technology is that structural formula II I compound and S-diethyl carboxylic acid halides Propanolamine (structural formula XI compound) direct reaction are obtained Linezolid, are called for short diethyl carboxylic acid halides Propanolamine technology, shown in figure 04.
Because S-diethyl carboxylic acid halides Propanolamine needs by following prepared (Fig. 5), and the difficult crystallization of S-halogen Propanolamine (structural formula XV compound), yield is low, influences whole technology cost, is not suitable for industrial production.
Pfizer improved above-mentioned technology in 2007, had reported the operational path (WO2007116284, CN200780012580.4) of a synthetic Linezolid again, was called for short imidohydrine technology, and is as shown in Figure 6.
There is following shortcoming in this technology:
When 1, preparing structural formula XVI compound, the reaction times needs more than 20 hour, and is oversize, is unfavorable for improving producing.Need in addition behind recrystallisation solvents such as reaction solution (MTBE is a solvent) adding normal heptane, octane-iso, structural formula XVI compound could be separated out in crystallization.Because mixed solvent reclaims more difficult than single solvent, production cost is higher relatively.And normal heptane, octane-iso, MTBE are all inflammable and explosive, and the production safety risk is also big.
2, when isolating construction formula XVII compound, adopt to reaction solution (methylene dichloride is a solvent) to add methyl alcohol or Virahol condensing crystal mode repeatedly.Not only operate loaded down with trivial details; And methyl alcohol and methylene dichloride or Virahol and methylene dichloride ratio, quantity all are subject to the influence of working condition (like temperature, pressure and concentration time); Be difficult to stable and consistent; Cause the crystallization yield and the difficult quality of structural formula XVII compound stable, do not meet drug quality and guarantee requirement.In addition, adopt mixed solvent crystallization, separated from solvent reclaims also difficulty, produces uneconomical.
3, can by-product chlorobenzaldehyde or bromobenzaldehyde or 2,4 dichloro benzene formaldehyde or 2 during structural formula XVII compound hydrolysis, 6-dichlorobenzaldehyde or paranitrobenzaldehyde etc.These aldehyde are solid aldehyde, and reclaiming purification needs recrystallization, and cost is high, and yield is low.
Adopting methylene dichloride when 4, preparing the finished product Linezolid is reaction solvent, and ETHYLE ACETATE is recrystallisation solvent.Because methylene dichloride belongs to the II kind solvent, toxicity is bigger, and product safety has a big risk.In addition, because solvent residual amount receives strict control, production cost is higher relatively.
Therefore, press for a kind of safe, practical, prepare the technology of Linezolid cheaply.
Summary of the invention
The invention provides a kind of midbody that is used to prepare Linezolid,
R wherein
1Be hydrogen, alkyl or substituted alkyl, preferred R
1Be the alkyl or the substituted alkyl of hydrogen, a 1-5 carbon atom, most preferably R
1Be methyl, ethyl or sec.-propyl.
The present invention also provides a kind of method for preparing structural formula I compound, and this method comprises with the structural formula II compound as reaction raw materials.
Preferably with structural formula II compound and structural formula II I compound
Reaction, generating structure formula I compound.Most preferably in the presence of alkali, structural formula II compound and structural formula II I compound react generating structure formula I compound in organic solvent.
Structural formula II I compound is with reference to West China pharmaceutical journal 2007; 22:179, Tianjin Normal University's journal (natural science edition) 2005; 25:13 and Chinese pharmaceutical chemistry magazine 2003; The preparation of documents such as 13:28.
In this reaction:
The structural formula II compound, R
2Be preferably the alkyl or the substituted alkyl of H, a 1-5 carbon atom, most preferably R
2Be H, methyl, ethyl or sec.-propyl.
The mol ratio of structural formula II compound and structural formula II I compound is 0.1: 1-10: 1, preferred 0.5: 1-2: 1, most preferably 1: 1-1.5: 1
Alkali is metal alkyl compound, metal hydride, metal alkoxide compound and metal hydroxides.Preferred butyllithium, sodium hydride, hydrolith, sodium methylate, sodium ethylate, sodium tert-butoxide, potassium tert.-butoxide and trimethyl carbinol lithium, most preferably trimethyl carbinol lithium.
Organic solvent is halogenated alkane, ether, ester, nitrile, acid amides, sulfone class etc.Preferred methylene dichloride, chloroform, ether, MTBE, THF, dioxane, ETHYLE ACETATE, butylacetate, acetonitrile, N,N-DIMETHYLACETAMIDE or methyl-sulphoxide etc.Most preferably methylene dichloride or MTBE or THF.
Temperature of reaction: 0-100 ℃, preferred reflux temperature.
The mol ratio of alkali and structural formula II I compound is 0.1: 1-10: 1, preferred 0.5: 1-2: 1, most preferably 1: 1-2: 1.
The weight ratio of organic solvent and structural formula II I compound is 1: 1-100: 1, preferred 2: 1-20: 1, most preferably 3: 1-10: 1.
After reaction finished, structural formula I compound or warp extracted or obtain through recrystallization or through chromatography or by above-mentioned one or more purification process combined utilization.
In this preparation method, the structural formula II compound removes R
2Outside hydrogen, all the other also all are new compounds.Therefore, the present invention also provides one type of new compound, its structure shown in structural formula II, R wherein
2Be alkyl or substituted alkyl, preferred R
2Be the alkyl or the substituted alkyl of 1-5 carbon atom, most preferably R
2Be methyl, ethyl or sec.-propyl.
The present invention also provides a kind of method for preparing the structural formula II compound, it is characterized in that with S-epoxy chloropropane (structural formula XVIII) be reaction raw materials.Preferably with the S-epoxy chloropropane with to korenyl formaldehyde (structural formula XIX compound) reaction, generating structure formula II compound, most preferably with the S-epoxy chloropropane with korenyl formaldehyde and ammoniacal liquor are reacted in organic solvent, obtain the structural formula II compound.
Wherein:
To korenyl formaldehyde R
2Be alkyl or substituted alkyl, preferred R
2Be the alkyl or the substituted alkyl of 1-5 carbon atom, most preferably R
2Be methyl, ethyl or sec.-propyl.
All can be purchased korenyl formaldehyde and S-epoxy chloropropane.
Mol ratio to korenyl formaldehyde and S-epoxy chloropropane is 0.1: 1-10: 1, preferred 0.5: 1-2: 1, and most preferably 1: 1.
Ammoniacal liquor is preferably commercially available strong aqua, wherein NH
3With the mol ratio of S-epoxy chloropropane be 0.1: 1-10: 1, preferred 0.5: 1-4: 1, most preferably 1: 1-2: 1
Reaction solvent is alcohol, ether, halogenated alkane, nitrile, acid amides, sulfone class etc.Particular methanol, ethanol, ether, MTBE, THF, dioxane, acetonitrile, N,N-DIMETHYLACETAMIDE or methyl-sulphoxide etc.Most preferably methyl alcohol, ethanol, MTBE, THF.
Temperature of reaction: 0-100 ℃, preferred reflux temperature.
The structural formula II compound is used acid hydrolysis, with aceticanhydride or Acetyl Chloride 98Min. acetylize, can obtain Linezolid again.
Advantage of the present invention:
When 1, preparing the structural formula II compound, the reaction times only needs 6-8 hour, shortens half the during than the R=halogen.And the structural formula II compound is a direct crystallization from reaction solution, need not to resemble to add inflammable and explosive recrystallisation solvent the R=halogen, and is simple to operate, produces safer.Because recrystallisation solvent is a single solvent, more be prone to reclaim than mixed solvent, production cost is low, and is little to environmental influence.
2, structural formula I compound of the present invention crystallization in single Virahol, its advantage are the amount may command that Virahol adds, and the crystallization yield and the steady quality of structural formula I compound are simple to operate, and yield is high, and cost is low, meets quality assurance requirements.On the contrary; When the R=halogen, WO2007116284 adopts to reaction solution (methylene dichloride is a solvent) and adds methyl alcohol or Virahol condensing crystal mode isolating construction formula I compound repeatedly, not only operates loaded down with trivial details; And the influence of temperature, pressure and distillation time when receiving to concentrate; Methyl alcohol and methylene dichloride or Virahol and methylene dichloride ratio and numbers of poles are difficult stable, and then the yield of structural formula I compound crystal is also unstable with quality, does not meet drug quality assurance requirement.
3, during structural formula I compound hydrolysis the aldehyde of by-product be phenyl aldehyde, p-tolyl aldehyde, to ethylbenzene formaldehyde or cumic aldehyde.These aldehyde all are liquid aldehydes, can directly apply mechanically after the alkali cleaning dehydration.On the contrary, when the R=halogen, by-product be chlorobenzaldehyde, bromobenzaldehyde, 2,4 dichloro benzene formaldehyde, 2,6-dichlorobenzaldehyde or paranitrobenzaldehyde etc.These aldehyde are solid aldehyde.The solid aldin does not wash clean, and needs recrystallization, needs baking, and cost recovery is high, and yield is low, complex operation.
4, when preparation finished product Linezolid, reaction solvent of the present invention and recrystallisation solvent all are ETHYLE ACETATE.What its advantage was not only the present invention's use is single solvent, and solvent recovering rate is high, and cost is low.The more important thing is that ETHYLE ACETATE is the reaction solvent methylene dichloride (II kind solvent) that the III kind solvent need be used during than the R=halogen, toxicity is little, and product is safer, and is also little to environmental influence.
Embodiment
The first step
Embodiment 1: (S)-and 1-chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula II, R
2=H) preparation
In the 500ml reaction flask, add the 53.1g phenyl aldehyde, 175ml 95% ethanol and 45.7g ammoniacal liquor (28.8%) stirred 10 minutes, added S-epoxy chloropropane 46.3g, and exothermic heat of reaction stirred 1 hour, and temperature rises to about 40 ℃ voluntarily.The heating, be incubated 35-40 ℃, reacted 6 hours, stirring at room is 13.5 hours again, is concentrated into about 50ml, crystallisation by cooling leaches solid, dry (S)-1-chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula II, R
2=H).
1H NMR (400MHz, CDCl
3): 2.80 (bs, 1H, OH), 3.67-3.69 (m, 2H, NCH
2), 3.76-3.87 (m, 2H, ClCH
2), 4.13-4.17 (m, 1H, OCH), 7.43-7.76 (m, 5H, phenyl ring H), 8.36 (S, 1H, N=CH).
Embodiment 2: (S)-and 1-chloro-3-[[(4-aminomethyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
3) preparation substitute the 53.1g phenyl aldehyde with the 60g p-tolyl aldehyde, all the other are constant, press embodiment 1 and operate, and can make
(S)-1-chloro-3-[[(4-aminomethyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
3).
1H NMR (400MHz, CDCl
3): 2.39 (s, 3H, CH
3), 2.88 (bs, 1H, OH), 3.64-3.67 (m, 2H, NCH
2), 3.75-3.82 (m, 2H, ClCH
2), 4.10-4.13 (m, 1H, OCH), 7.21-7.64 (dd, 4H, phenyl ring H), 8.31 (S, 1H, N=CH).
Embodiment 3: (S)-and 1-chloro-3-[[(4-ethylphenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
2CH
3) preparation
With 67.1g ethylbenzene formaldehyde is substituted the 53.1g phenyl aldehyde, all the other are constant, press embodiment 1 operation, can make (S)-1-chloro-3-[[(4-ethylphenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
2CH
3).
1H NMR (400MHz, CDCl
3): 1.10 (T, 3H, CH
3), 2.56 (Q, 2H, CH
2), 2.87 (bs, 1H, OH), 3.64-3.67 (m, 2H, NCH
2), 3.75-3.84 (m, 2H, ClCH
2), 4.10-4.14 (m, 1H, OCH), 7.22-7.64 (dd, 4H, phenyl ring H), 8.32 (S, 1H, N=CH).
Embodiment 4: (S)-and 1-chloro-3-[[(4-isopropyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
3CHCH
3) preparation
Substitute the 53.1g phenyl aldehyde with the 74.1g cumic aldehyde, all the other are constant, press embodiment 1 operation, can make (S)-1-chloro-3-[[(4-isopropyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH3CHCH3).
1H NMR (400MHz, CDCl
3): 1.13 (d, 6H, CH (CH
3)
2), 2.84 (bs, 1H, OH), 2.88-2.92 (m, 1H, (CH
3)
2CH), 3.65-3.69 (m, 2H, NCH
2), 3.75-3.84 (m, 2H, ClCH
2), 4.11-4.14 (m, 1H, OCH), 7.20-7.64 (dd, 4H, phenyl ring H), 8.33 (S, 1H, N=CH).
Second step
Embodiment 5: (S)-and [[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H) preparation
(structural formula 16, R2=H) 17.79g dissolve among the methylene dichloride 40ml subsequent use with (S)-1-chloro-3-[(phenyl methyne) amino] propan-2-ol.
With carbobenzoxy-(Cbz)-3-fluoro-4-morpholine aniline 19.82g, trimethyl carbinol lithium 12.01g and methylene dichloride 80ml; Put in the reaction flask stirring at room, above-mentioned (the S)-1-of disposable adding chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula 16; R2=H) dichloromethane solution; Stir, heating refluxed 10 hours.Reaction solution is cooled to room temperature.Water 100ml, 50ml washing reaction liquid successively.Organic phase is used anhydrous magnesium sulfate drying, filter, filtrating is concentrated into dried.Add Virahol, stir, crystallization under the-20--10 ℃ of condition leaches crystallization, and 50 ℃ of vacuum-dryings get (S)-[[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H).
1H NMR (400MHz, CDCl
3): 3.06 (t, 4H, 2NCH
2), 3.88 (t, 4H, 2OCH
2), 3.90-3.99 (m, 2H ,=NCH
2), 4.06-4.12 (m, 2H, OCNCH
2), 4.93-4.97 (m, 1H, HOCH), 6.90-7.70 (m, 8H, phenyl ring hydrogen), 8.40 (s, 1H, N=CH).
Embodiment 6: (S)-and [[[(4-aminomethyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3) preparation
With (S)-1-chloro-3-[[(4-aminomethyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
3) alternative (S)-1-chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula II of 19.05g; R2=H) 17.79g; All the other are constant; Press embodiment 5 operations, can make (S)-[[[(4-aminomethyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3).
1H NMR (400MHz, CDCl
3): 2.38 (s, 3H, CH
3), 3.06 (t, 4H, 2NCH
2), 3.87 (t, 4H, 2OCH
2), 3.85-4.01 (m, 2H ,=NCH
2), 4.02-4.14 (m, 2H, OCNCH
2), 4.92-4.96 (m, 1H, HOCH), 6.90-7.60 (m, 7H, phenyl ring hydrogen), 8.35 (s, 1H, N=CH).
Embodiment 7: (S)-and [[[(4-ethylphenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
2CH
3) preparation
With (S)-1-chloro-3-[[(4-ethylphenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
2CH
3) alternative (S)-1-chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula II of 20.31g; R2=H) 17.79g; All the other are constant; Press embodiment 5 operations, can make (S)-[[[(4-ethylphenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
2CH
3).
1H NMR (400MHz, CDCl
3): 1.10 (T, 3H, CH
3), 2.57 (Q, 2H, CH
2), 3.06 (t, 4H, 2NCH
2), 3.87 (t, 4H, 2OCH
2), 3.87-4.01 (m, 2H ,=NCH
2), 4.03-4.15 (m, 2H, OCNCH
2), 4.92-4.96 (m, 1H, HOCH), 6.90-7.60 (m, 7H, phenyl ring hydrogen), 8.34 (s, 1H, N=CH).
Embodiment 8: (S)-and [[[(4-isopropyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3CHCH
3) preparation
With (S)-1-chloro-3-[[(4-isopropyl phenyl) methyne] amino] propan-2-ol (structural formula II, R
2=CH
3CHCH
3) 21.58g alternative (S)-1-chloro-3-[(phenyl methyne) amino] propan-2-ol (structural formula II, R
2=H) 17.79g, all the other are constant, press embodiment 5 operations, can make (S)-[[[(4-isopropyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3CHCH
3).
1H NMR (400MHz, CDCl
3): 1.12 (d, 6H, CH (CH
3)
2), 2.87-2.92 (m, 1H, (CH
3)
2CH), 3.06 (t, 4H, 2NCH
2), 3.86 (t, 4H, 2OCH
2), 3.85-4.01 (m, 2H ,=NCH
2), 4.04-4.16 (m, 2H, OCNCH
2), 4.92-4.97 (m, 1H, HOCH), 6.90-7.61 (m, 7H, phenyl ring hydrogen), 8.38 (s, 1H, N=CH). the 3rd step
Embodiment 9: the preparation of Linezolid
With (S)-[[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H) 11.5g, acetate acetate 90ml, water 90ml mixes and stirs, and adds 12M concentrated hydrochloric acid 5.0ml, and behind the several minutes, solid gets into solution, continues to stir 2 hours, and HPLC analyzes and shows that hydrolysis reaction is complete.Divide and remove organic phase, water is washed once with ETHYLE ACETATE 50ml again, the reject organic phase.Add ETHYLE ACETATE 90ml to water, transfer pH value 6.7 (about 4.8g), tell organic phase with 50% sodium hydroxide; Water extracts once with ETHYLE ACETATE 50ml again, combining extraction liquid, and washing is once; Anhydrous magnesium sulfate drying filters filtering sal epsom; Add aceticanhydride 6.13g, filtrating is concentrated into 50ml, 0 ℃ of crystallization.Suction filtration leaches crystallization, 50 ℃ of following vacuum-dryings naphthalene azoles amine of getting profit.
Embodiment 10: the preparation of Linezolid
With (S)-[[[(4-aminomethyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3) 11.9g replacement (S)-[[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H) 11.5g, all the other are constant, by implementing 9 operations, can make Linezolid.
Embodiment 11: the preparation of Linezolid
With (S)-[[[(4-ethylphenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
2CH
3) 12.3g replacement (S)-[[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H) 11.5g, all the other are constant, by implementing 9 operations, can make Linezolid.
Embodiment 12: the preparation of Linezolid
With (S)-[[[(4-isopropyl phenyl) methyne] amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=CH
3CHCH
3) 12.8g replacement (S)-[[(phenyl methyne) amino] methyl]-3-(3-fluoro-4-morpholine-4-base phenyl) oxazolidine-2-ketone (structural formula I, R
1=H) 11.5g, all the other are constant, by implementing 9 operations, can make Linezolid.
Claims (8)
1. compound is characterized in that it is shown in structural formula I:
R wherein
1Alkyl for hydrogen or 1-5 carbon atom.
2. compound according to claim 1, wherein said R
1Be methyl, ethyl or sec.-propyl.
3. the preparation method of the said compound of structural formula I is characterized in that, comprises structural formula II compound as follows
R wherein
2Alkyl for hydrogen or 1-5 carbon atom.
With structural formula II I compound
Reaction obtains the step of structural formula I compound.
4. preparation method according to claim 3, the wherein R in the structural formula II
2Be methyl, ethyl or sec.-propyl.
5. compound is characterized in that it is shown in structural formula II:
R wherein
2Alkyl for 1-5 carbon atom.
6. compound according to claim 5, wherein said R
2Be methyl, ethyl or sec.-propyl.
7. the preparation method of the said compound of structural formula II is characterized in that, comprises S-epoxy chloropropane and structural formula XIX compound and ammoniacal liquor reaction as follows, obtains the structural formula II compound
R wherein
2Alkyl for 1-5 carbon atom.
8. preparation method according to claim 7, wherein R
2Be methyl, ethyl or sec.-propyl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110033294A CN102153521B (en) | 2011-01-31 | 2011-01-31 | Intermediate for preparing linezolid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110033294A CN102153521B (en) | 2011-01-31 | 2011-01-31 | Intermediate for preparing linezolid and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102153521A CN102153521A (en) | 2011-08-17 |
| CN102153521B true CN102153521B (en) | 2012-09-12 |
Family
ID=44435237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110033294A Expired - Fee Related CN102153521B (en) | 2011-01-31 | 2011-01-31 | Intermediate for preparing linezolid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102153521B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626712B (en) * | 2012-08-23 | 2016-06-01 | 重庆药友制药有限责任公司 | A kind of intermediate for the preparation of Linezolid and its preparation method |
| CN105566242B (en) * | 2016-01-12 | 2017-12-05 | 江苏豪森药业集团有限公司 | The preparation method of Linezolid and its intermediate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837870A (en) * | 1996-04-11 | 1998-11-17 | Pharmacia & Upjohn Company | Process to prepare oxazolidinones |
| CN101415694A (en) * | 2006-04-07 | 2009-04-22 | 辉瑞产品公司 | Process for preparing linezolid |
-
2011
- 2011-01-31 CN CN201110033294A patent/CN102153521B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837870A (en) * | 1996-04-11 | 1998-11-17 | Pharmacia & Upjohn Company | Process to prepare oxazolidinones |
| CN101415694A (en) * | 2006-04-07 | 2009-04-22 | 辉瑞产品公司 | Process for preparing linezolid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102153521A (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ306898A3 (en) | Piperazine and piperidine compounds, process of their preparation and pharmaceutical compositions containing thereof | |
| CN106632298B (en) | Preparation method and intermediate of tedizolid | |
| EP2722330B1 (en) | Novel method for synthesizing rivaroxaban intermediate, 4-{4-[(5s)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one | |
| CN102850376B (en) | One-step synthesizing method of levofloxacin and ofloxacin | |
| KR101582697B1 (en) | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | |
| CN102153521B (en) | Intermediate for preparing linezolid and preparation method thereof | |
| JP2009522210A (en) | 2,2 ', 6,6'-tetraoxazoline biphenyl ligand and method for preparing the same | |
| CN102491953A (en) | Method for synthesizing florfenicol midbody RT0131 | |
| CN102911160A (en) | Method for preparing and purifying dabigatran etexilate intermediate | |
| CN105745191A (en) | Method for preparing silodosin and intermediate thereof | |
| CN113956243A (en) | Rosuvastatin intermediate and preparation method thereof | |
| CN109320510B (en) | Preparation method of Maropitan free base | |
| JPH0136462B2 (en) | ||
| AU2018389809B2 (en) | A process for the preparation of crisaborole | |
| CN103626712B (en) | A kind of intermediate for the preparation of Linezolid and its preparation method | |
| EP0823907B1 (en) | PROCESS FOR PREPARING (-)-TRANS-N-p-FLUOROBENZOYLMETHYL-4-(p-FLUOROPHENYL)-3-[[3,4-(METHYLENEDIOXY)PHENOXY]METHYL]-PIPERIDINE | |
| CN114716428B (en) | Method for preparing metazopyr intermediate | |
| EP3906235B1 (en) | Method for preparing sulfonamides drugs | |
| CN116947691B (en) | Preparation method of fluvoxamine maleate | |
| CN111747874B (en) | Ericoxib intermediate and preparation method and application thereof | |
| CN101215274B (en) | Technique for preparing N-substituted morpholines organic compounds | |
| JP4568824B2 (en) | Method for producing diarylsulfonic acid derivative | |
| CN111747873A (en) | Ericoxib intermediate and preparation method and application thereof | |
| CN104860904B (en) | N-glycidyl-N-anilid compounds Preparation Method And The Use | |
| CN110746371A (en) | Intermediate for preparing aprepitant and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Ningbo Yinzhou Baitejia Pharmaceutical Co., Ltd. Document name: Notification to Pay the Fees |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120912 Termination date: 20130131 |